akr-501 and Nausea

akr-501 has been researched along with Nausea* in 1 studies

Trials

1 trial(s) available for akr-501 and Nausea

ArticleYear
Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Journal of hepatology, 2014, Volume: 61, Issue:6

    This is a phase II multicentre study to investigate the efficacy and safety of avatrombopag (E5501), an investigational second-generation thrombopoietin receptor agonist, administered one week prior to elective procedures in patients with thrombocytopenia secondary to cirrhosis.. Adults with cirrhosis and platelet counts ⩾10 to ⩽58×10(9)/L were randomized to placebo or avatrombopag in two sequential cohorts. Cohort A: placebo vs. one of 3 different doses (100mg loading dose followed by 20, 40, or 80 mg/day on days 2-7) of a first-generation avatrombopag formulation. Cohort B: placebo vs. one of 2 different doses (80 mg loading dose followed by 10 mg/day for days 2-7, or 20mg/day for days 2-4) of a second-generation avatrombopag formulation. Primary end point was achievement of a platelet increase of ⩾20×10(9)/L from baseline and >50×10(9)/L at least once during days 4-8.. A total of 130 patients were randomized: 93 patients (51, cohort A; 42, cohort B) to avatrombopag and 37 (16, cohort A; 21 cohort B) to placebo. The primary end point was achieved by 49.0% of treated patients in cohort A and 47.6% in cohort B compared to 6.3% and 9.5% of controls; a dose response was seen. Each avatrombopag regimen had a higher proportion of responders compared with their respective cohort placebo arms (p<0.01), except for the 100/40 mg group in cohort A (p=0.17). The most common adverse events were nausea, fatigue, and headache. One patient in the (100/80) avatrombopag group, without a Doppler assessment at screening was diagnosed with portal vein thrombosis during post-treatment follow-up.. In this study avatrombopag was generally well-tolerated and increased platelet counts in patients with cirrhosis undergoing elective invasive procedures.

    Topics: Blood Platelets; Dose-Response Relationship, Drug; Double-Blind Method; Elective Surgical Procedures; Fatigue; Female; Headache; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Nausea; Platelet Count; Receptors, Thrombopoietin; Risk Factors; Thiazoles; Thiophenes; Thrombocytopenia

2014